Premium
AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE‐BLIND PLACEBO CONTROLLED‐CLINICAL TRIAL
Author(s) -
Ghanizadeh Ahmad,
Hedayati Arvin
Publication year - 2013
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/da.22195
Subject(s) - lovastatin , placebo , fluoxetine , major depressive disorder , depression (economics) , medicine , randomized controlled trial , hamilton rating scale for depression , adverse effect , rating scale , psychiatry , psychology , cholesterol , receptor , pathology , amygdala , serotonin , economics , macroeconomics , developmental psychology , alternative medicine
Backgrounds There are contradictory evidence about the effect of statins on depression. This 6‐week‐randomized placebo‐controlled clinical trial assessed the efficacy and safety of lovastatin as an adjuvant agent for treating major depressive disorder ( MDD ). Methods The participants were 68 patients with MDD according to DSM ‐ IV diagnostic criteria. The sample was randomly allocated into fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day) group or fluoxetine plus placebo group. H amilton D epression R ating scale was used to measure depression score at baseline, week 2, and week 6. Results Both groups showed a significant decrease of depression score on the H amilton D epression scale. However, the treatment group decreased depression score more than placebo group [12.8(6.3) vs. 8.2(4.0), t = 3.4, df = 60, P < .001]. Any serious adverse effect was not found. Discussion These results suggest that lovastatin as an adjuvant treatment may be effective for treating patients with MDD .